Login to Your Account



Seeking Priority Review

NPS Files Gattex NDA in SBS; Commercial Plan 'Set in Motion'

By Jennifer Boggs
Managing Editor

Friday, December 2, 2011
NPS Pharmaceuticals Inc. completed its new drug application (NDA) submission for Gattex (teduglutide) in short bowel syndrome (SBS), seeking a priority six-month review that could see the orphan drug on the market in the first half of next year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription